A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Elizabeth Ruth Plummer, Udai Banerji(Institute of Cancer Research), T.R. Jeffry Evans(University of Glasgow), Mark Kowalski(College of San Mateo), Harriet S. Walter(Leicester Royal Infirmary), Louise Carter(The Christie NHS Foundation Trust), Stefan N. Symeonides(Edinburgh Cancer Research), Elena Cojocaru(Institut Gustave Roussy), Robert H. Jones(Clinical Research Institute), Sarah P. Blagden(Churchill Hospital), Andrew Dye(Sierra Wireless (Canada)), Sarah Danson(Weston Park Cancer Centre), Ines Verdon(Sierra Wireless (Canada)), Rebecca Kristeleit(King's College London), Debashis Sarker(King's College - North Carolina), Manreet Randhawa(Beatson West of Scotland Cancer Centre), Joanita Ocen, Noor Md Haris(Freeman Hospital), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute)
Cited by 31
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
|British Journal of Cancer|2015|638